KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Deferred Taxes: 2009-2024

Historic Deferred Taxes for Alnylam Pharmaceuticals (ALNY) over the last 5 years, with Dec 2024 value amounting to -$106.8 million.

  • Alnylam Pharmaceuticals' Deferred Taxes rose 3534.36% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.4 million, marking a year-over-year decrease of 816.33%. This contributed to the annual value of -$106.8 million for FY2024, which is 14873.63% down from last year.
  • According to the latest figures from FY2024, Alnylam Pharmaceuticals' Deferred Taxes is -$106.8 million, which was down 14,873.63% from -$713,000 recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Deferred Taxes registered a high of -$713,000 during FY2023, and its lowest value of -$106.8 million during FY2024.
  • In the last 3 years, Alnylam Pharmaceuticals' Deferred Taxes had a median value of -$1.4 million in 2022 and averaged -$36.3 million.
  • Its Deferred Taxes has fluctuated over the past 5 years, first soared by 50.24% in 2023, then tumbled by 14,873.63% in 2024.
  • Over the past 3 years, Alnylam Pharmaceuticals' Deferred Taxes (Yearly) stood at -$1.4 million in 2022, then spiked by 50.24% to -$713,000 in 2023, then plummeted by 14,873.63% to -$106.8 million in 2024.